Dr. Huang Cheng has more than 20 years' of experience in clinical development. He has led clinical trials for multinational pharmaceutical enterprises such as AstraZeneca, Boehringer Ingelheim, Abbott, Hutchison Medipharma, and Generon, in areas of oncology, respiratory, digestive, cardiovascular, rheumatic and immune diseases. Dr. Huang has led various domestic and international trials, involving Nexium, Humira, sufentinib, furquitinib, voritinib, long-acting G-CSF fusion protein, IL-22 fusion protein, CD3 × EpCAM and CD3 × CD19 bispecific antibodies, etc., that were registered or conducted internationally. Before joining ImmuneOnco, Dr. Huang was the head of Medical Department of Lee's Pharmaceutical Group.
He graduated from Shanghai Second Medical University (now medical school of Shanghai Jiaotong University) with M.D. degree, and subsequently obtained a master's degree in public health from Fudan University.